This overview from ACC 2026 examines how emerging data, including findings from SCOUT-HCM and other myosin inhibitor trials, are reshaping management of hypertrophic cardiomyopathy (HCM). Dr. Joseph Rossano highlights the shift from reactive, symptom-based care to strategies that target underlying disease pathophysiology. He also underscores the importance of early identification of symptomatic obstructive HCM, timely imaging and referral, and consideration of disease-targeted therapy. Tune in to see how these insights can inform real-world care across the HCM spectrum.
advertisement
Hypertrophic Cardiomyopathy: Moving From Monitoring to Action in the Era of Myosin Inhibitors
Share
Save
Restart
Resume
Transcript
Hypertrophic Cardiomyopathy: Moving From Monitoring to Action in the Era of Myosin Inhibitors
closeShare this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Presenters
Related
Overview
Provider(s)/Educational Partner(s)
Global Learning Collaborative (GLC) designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. GLC’s methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the best education in the most impactful manner and to verify its results with progressive outcomes research.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.
Recommended
Details
Presenters
Related
Overview
This overview from ACC 2026 examines how emerging data, including findings from SCOUT-HCM and other myosin inhibitor trials, are reshaping management of hypertrophic cardiomyopathy (HCM). Dr. Joseph Rossano highlights the shift from reactive, symptom-based care to strategies that target underlying disease pathophysiology. He also underscores the importance of early identification of symptomatic obstructive HCM, timely imaging and referral, and consideration of disease-targeted therapy. Tune in to see how these insights can inform real-world care across the HCM spectrum.
Provider(s)/Educational Partner(s)
Global Learning Collaborative (GLC) designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. GLC’s methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the best education in the most impactful manner and to verify its results with progressive outcomes research.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
advertisement
Recommended
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?